- Home
- / Janux Therapeutics
Janux Therapeutics
Stock Price
$54.2
2024-10-29
Market Capitalization
$2.8 B
2024-10-29
Revenue
$10 M
FY, 2025
Janux Therapeutics Summary
Company Summary
- Overview
- Janux Therapeutics is a biopharmaceutical company developing therapeutics to treat patients with cancer. It develops Tumor Activated T-Cell Engager (TRACTr) platform and its lead product candidates are designed to target clinically validated drug targets.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- San Diego, CA, US | view all locations
- Website
- https://www.januxrx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Tighe Reardon, Acting CFO
Wayne Godfrey, Chief Medical Officer
Andy Meyer, Chief Business Officer
LocationsView all
1 location detected
San Diego, CA HQ
United States
11099 N Torrey Pines Rd # 290, La Jolla
Janux Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $3.7M
- Net income (Q1, 2026)
- ($24.4M)
- Cash (Q1, 2026)
- $51.8M
- EBIT (Q1, 2026)
- ($34.2M)
- Enterprise value
- $2.8B